EXHIBIT 10.41 POLICY OF ENDO PHARMACEUTICALS HOLDINGS INC. RELATING TO INSIDER TRADING IN COMPANY SECURITIES AND CONFIDENTIALITY OF INFORMATION

EXHIBIT 10.41

POLICY OF ENDO PHARMACEUTICALS HOLDINGS INC.
RELATING TO INSIDER TRADING IN COMPANY
SECURITIES AND CONFIDENTIALITY OF INFORMATION

      The Board of Directors has adopted the following Policy which applies to all personnel (including directors and officers) of Endo Pharmaceuticals Holdings Inc. and its subsidiaries (collectively called the “Company”) arising from our legal and ethical responsibilities as a public company.

      1. Prohibition Against Trading on Undisclosed Material Information: If you are aware of material information relating to the Company which has not yet been available to the public for at least two full days (often called “inside information”), you are prohibited from trading in our securities, directly or indirectly, and from disclosing such information to any other persons who may trade in our securities. Any information, positive or negative, is “material” if it might be of significance to an investor in determining whether to purchase, sell or hold our securities. Information may be significant for this purpose even if it would not alone determine the investor’s decision. Examples include a potential business acquisition, internal information about revenues, earnings or other aspects of financial performance which departs in any way from what the market would expect based upon prior disclosures, important business developments (including FDA approval or nonapproval of one of our products), the acquisition or loss of major customer, or an i